CF
ALXN

Copperwynd Financial’s Alexion Pharmaceuticals ALXN Stock Holding History

Copperwynd Financial’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,730
Closed -$685K – 129
2021
Q2 		$685K Buy
3,730
+15
+0.4% +$2.58K 0.29% 54
2021
Q1 		$568K Sell
3,715
-127
-3% -$19.6K 0.26% 63
2020
Q4 		$600K Sell
3,842
-253
-6% -$32.5K 0.29% 54
2020
Q3 		$469K Sell
4,095
-80
-2% -$8.63K 0.25% 66
2020
Q2 		$469K Sell
4,175
-391
-9% -$41.5K 0.27% 59
2020
Q1 		$410K Buy
4,566
+825
+22% +$81K 0.19% 51
2019
Q4 		$405K Sell
3,741
-454
-11% -$48.6K 0.21% 92
2019
Q3 		$453K Buy
+4,195
New +$473K 0.26% 88

Other funds holding ALXN

Brinker Capital Investments
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TD Ameritrade Investment Management
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Copperwynd Financial's ALXN Position: Q3 2021 in Review

Copperwynd Financial sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 3,730 shares — an estimated $685K sold.

Copperwynd Financial first reported a position in ALXN in Q3 2019 and held it in 8 quarters. The position peaked at $685K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Copperwynd Financial reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Copperwynd Financial sold 3,730 Alexion Pharmaceuticals shares in Q3 2021, an estimated $685K.
  • Copperwynd Financial first reported a position in Alexion Pharmaceuticals in Q3 2019 and held it in 8 quarters.
  • Copperwynd Financial's Alexion Pharmaceuticals position peaked at $685K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Copperwynd Financial's 13F filing for Q3 2021, filed 3 Nov 2021.